Skip to main content

Table 1 Summary of the 50% inhibition concentration (IC50) of evofosfamide in nasopharyngeal carcinoma cell lines

From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo

Cell line

IC50 of evofosfamide

HCR (N/H)

N (μmol/L)

H (μmol/L)

CNE-2

77.62 ± 8.86

8.33 ± 0.75**

9

HONE-1

87.18 ± 19.19

7.62 ± 0.67**

11

HNE-1

103.97 ± 12.91

0.31 ± 0.07**

335

  1. N normoxia, H hypoxia, HCR hypoxia cytotoxicity ratio
  2. **P < 0.01
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us